CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 63 enrolled
Drug / intervention
Posaconazoledrug
Likely dose
Posaconazole 400mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00811642
NCT00811642Phase 3Completed
CompareCT.gov

A Multicenter, Open Label Study to Evaluate Safety and Efficacy of Posaconazole Oral Suspension in Treatment of Invasive Fungal Infection

Merck Sharp & Dohme LLC·interventional·Posted Dec 19, 2008·Updated Apr 7, 2017

In Brief

A Phase 3 clinical trial evaluating Posaconazole for Fungal Infection. Completed, enrolled 63 participants.

Detailed Summary

The purpose of this multicenter, open label study, is to evaluate the safety and efficacy of a 12-week treatment with Posaconazole Oral Suspension in participants with IFI

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFungal Infection
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 19, 2008
Enrollment StartNov 1, 2008
Primary CompletionMar 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 17.5 years ago

Interventions

Posaconazoledrug

400mg BID oral suspension for 12 weeks